Last reviewed · How we verify
Combination of liposomal doxorubicin
Combination of liposomal doxorubicin is a Small molecule drug developed by Mridula George, MD. It is currently in Phase 2 development.
At a glance
| Generic name | Combination of liposomal doxorubicin |
|---|---|
| Sponsor | Mridula George, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of liposomal doxorubicin CI brief — competitive landscape report
- Combination of liposomal doxorubicin updates RSS · CI watch RSS
- Mridula George, MD portfolio CI
Frequently asked questions about Combination of liposomal doxorubicin
What is Combination of liposomal doxorubicin?
Combination of liposomal doxorubicin is a Small molecule drug developed by Mridula George, MD.
Who makes Combination of liposomal doxorubicin?
Combination of liposomal doxorubicin is developed by Mridula George, MD (see full Mridula George, MD pipeline at /company/mridula-george-md).
What development phase is Combination of liposomal doxorubicin in?
Combination of liposomal doxorubicin is in Phase 2.